Date published: 2026-5-4

1-800-457-3801

SCBT Portrait Logo
Seach Input

GAK Inhibitors

GAK inhibitors encompass a variety of compounds that interfere with the kinase's activity or its cellular signaling pathways. While not all compounds specifically target GAK, they are capable of modulating its function due to their action on kinases and related cell cycle or signaling components. Compounds such as alsterpaullone, roscovitine, and flavopiridol are known for their inhibitory effects on cyclin-dependent kinases (CDKs), which share functional similarities with GAK, particularly in their roles in cell cycle regulation and signal transduction. By inhibiting these kinases, the compounds may indirectly affect GAK's activity. The chemical class of GAK inhibitors is not limited to direct kinase inhibition but also includes agents that disrupt kinase-associated pathways. For instance, hesperadin, an Aurora kinase inhibitor, may alter the cellular environment in which GAK operates, thereby affecting its function. Similarly, SP600125, as a JNK inhibitor, could influence stress-responsive pathways that intersect with GAK-mediated processes. The indirect inhibitors highlight the interconnected nature of cellular signaling, where perturbing one component can ripple through the network, impacting related proteins like GAK. These inhibitors, with their diverse chemical structures and mechanisms of action, offer insight into the complex regulation of kinase activity and the potential to modulate it through different molecular interactions.

Items 1 to 10 of 13 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB 203580 is a selective inhibitor that targets the p38 mitogen-activated protein kinase (MAPK) pathway, exhibiting unique molecular interactions that modulate cellular stress responses. Its structure allows for specific binding to the ATP-binding site, altering phosphorylation dynamics and influencing downstream signaling cascades. The compound's hydrophobic regions enhance membrane permeability, affecting its distribution and interaction with various cellular compartments, thereby impacting cellular function.

Alsterpaullone

237430-03-4sc-202453
sc-202453A
1 mg
5 mg
$68.00
$312.00
2
(1)

Alsterpaullone is a cyclin-dependent kinase inhibitor that may inhibit GAK by affecting its association with cyclins.

Roscovitine

186692-46-6sc-24002
sc-24002A
1 mg
5 mg
$94.00
$265.00
42
(2)

Roscovitine targets various cyclin-dependent kinases and could impede GAK's kinase activity by competitive inhibition.

Indirubin-3′-monoxime

160807-49-8sc-202660
sc-202660A
sc-202660B
1 mg
5 mg
50 mg
$79.00
$321.00
$671.00
1
(1)

This compound is a CDK inhibitor that might also inhibit GAK due to its role in cell cycle regulation.

Hesperadin

422513-13-1sc-490384
10 mg
$304.00
(0)

Hesperadin is an Aurora kinase inhibitor, which could indirectly affect GAK by altering cell cycle progression.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

As a JNK inhibitor, SP600125 can modulate stress-response pathways potentially related to GAK's functions.

5-Iodotubercidin

24386-93-4sc-3531
sc-3531A
1 mg
5 mg
$153.00
$464.00
20
(2)

This adenosine analog inhibits various kinases and could non-selectively inhibit GAK's ATP-binding site.

Harmine

442-51-3sc-202644
sc-202644A
sc-202644B
sc-202644C
sc-202644D
sc-202644E
sc-202644F
250 mg
500 mg
1 g
10 g
50 g
100 g
500 g
$53.00
$104.00
$126.00
$551.00
$1467.00
$2611.00
$11455.00
2
(2)

Harmine is a DYRK inhibitor that might affect GAK activity through overlaps in substrate specificity or pathway interaction.

Purvalanol A

212844-53-6sc-224244
sc-224244A
1 mg
5 mg
$72.00
$297.00
4
(2)

Purvalanol A is a CDK inhibitor that could also inhibit GAK, impacting cell cycle and transcription regulation.

Dinaciclib

779353-01-4sc-364483
sc-364483A
5 mg
25 mg
$247.00
$888.00
1
(0)

Dinaciclib strongly inhibits CDKs and might inhibit GAK, potentially affecting downstream signaling.